CB-01-33 (Colesevelam) is a bile acid sequestrant approved in the USA in May 2000 for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia.
Our Colesevelam (CB-01-33), formulated with Cosmo’s proprietary technology, has the potential to overcome the current concerns for bile acid sequestrants for the treatment of bile acid diarrhea (BAD).
Bile Acid Diarrhea (BAD) is reported in about 25%-33% of patients presenting with chronic diarrhea. Based on this data, BAD is estimated to affect approximately 1% of the population.
The product is currently in the formulation development phase.